1-10 of 10
Andrew W. Roberts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Clinical Trials & Observations
Stephan Stilgenbauer, Eugen Tausch, Andrew W. Roberts, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P. Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T. Ghanim, Michael Moran, Wendy J. Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G. Wierda, John F. Seymour
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1992–2004.
https://doi.org/10.1182/bloodadvances.2023011741
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary A. Anderson
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1439–1443.
https://doi.org/10.1182/bloodadvances.2023011327
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells

Clinical Trials & Observations
Charis E. Teh, Hongke Peng, Meng-Xiao Luo, Tania Tan, Marie Trussart, Lauren J. Howson, Chong Chyn Chua, Christine Muttiah, Fiona Brown, Matthew E. Ritchie, Andrew H. Wei, Andrew W. Roberts, Vanessa L. Bryant, Mary Ann Anderson, Geoffrey J. Lindeman, David C. S. Huang, Rachel Thijssen, Daniel H. D. Gray
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2733–2745.
https://doi.org/10.1182/bloodadvances.2022008221
Published: 2023
Includes: Supplemental data
Journal Articles

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

Clinical Trials & Observations
Constantine S. Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, Judith Trotman, Stephen Opat, Andrew W. Roberts, Roger Owen, Yuqin Song, Wei Xu, Jun Zhu, Jianyong Li, Lugui Qiu, Shirley D’Sa, Wojciech Jurczak, Gavin Cull, Paula Marlton, David Gottlieb, Javier Munoz, Tycel Phillips, Chenmu Du, Meng Ji, Lei Zhou, Haiyi Guo, Hongjie Zhu, Wai Y. Chan, Aileen Cohen, William Novotny, Jane Huang, Alessandra Tedeschi
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1296–1308.
https://doi.org/10.1182/bloodadvances.2021005621
Published: 2022
Includes: Supplemental data
Journal Articles

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R. Thompson, Tamia Nguyen, Yamuna Kankanige, John F. Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David A. Westerman, Piers Blombery
Journal: Blood Advances
Blood Adv (2022) 6 (2): 503–508.
https://doi.org/10.1182/bloodadvances.2021006211
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Clinical Trials & Observations
Thomas E. Lew, Victor S. Lin, Edward R. Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4054–4058.
https://doi.org/10.1182/bloodadvances.2021005083
Published: 2021
Includes: Supplemental data
Journal Articles

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Clinical Trials & Observations
Joanne E. Davis, Sasanka M. Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, David S. Ritchie, Rachel M. Koldej
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4849–4859.
https://doi.org/10.1182/bloodadvances.2020002810
Published: 2020
Includes: Supplemental data
Journal Articles

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Donia M. Moujalled, Diane T. Hanna, Soroor Hediyeh-zadeh, Giovanna Pomilio, Lauren Brown, Veronique Litalien, Ray Bartolo, Shaun Fleming, Maïa Chanrion, Sébastien Banquet, Ana-Leticia Maragno, Laurence Kraus-Berthier, Marie Schoumacher, Charles G. Mullighan, Angela Georgiou, Christine A. White, Guillaume Lessene, David C. S. Huang, Andrew W. Roberts, Olivier Geneste, Lorna Rasmussen, Melissa J. Davis, Paul G. Ekert, Andrew Wei, Ashley P. Ng, Seong L. Khaw
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2762–2767.
https://doi.org/10.1182/bloodadvances.2019001416
Published: 2020
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax: a primer

Clinical Trials & Observations
Andrew W. Roberts
Journal: Blood Advances
Blood Adv (2017) 1 (7): 467.
https://doi.org/10.1182/bloodadvances.2017000547
Published: 2017
Includes: Supplemental data